SCHEMBL4980169

SCHEMBL4980169

Nc1nc(Cl)c(NC=O)c(N[C@@H]2C=C[C@H](CO)C2)n1

nearest known ligand 0.37

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.37
ALB P02768 1/20 0.37
PDE4D Q08499 1/20 0.37
IRAK4 Q9NWZ3 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5117081 1.00 NR1I2 (0.37) NR1I2ALBPDE4DIRAK4
SCHEMBL14048880 1.00 NR1I2 (0.37) NR1I2ALBPDE4DIRAK4
SCHEMBL14049050 1.00 NR1I2 (0.37) NR1I2ALBPDE4DIRAK4
SCHEMBL331086 1.00 NR1I2 (0.37) NR1I2ALBPDE4DIRAK4
SCHEMBL4980179 1.00 NR1I2 (0.37) NR1I2ALBPDE4DIRAK4
SCHEMBL31454809 1.00 NR1I2 (0.37) NR1I2ALBPDE4DIRAK4
SCHEMBL7668284 1.00 NR1I2 (0.37) NR1I2ALBPDE4DIRAK4
SCHEMBL9842434 0.83
SCHEMBL8446237 0.83
SCHEMBL8446236 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1418170-B1 Process for the preparation of optically active amino alcohols by optical resolution LONZA AG (CH) 2006-06-07 EP claimed
EP-0878548-B1 Multistep process for the preparation of (1S,4R)- and/or (1R,4S)-4-(2-Amino-6-Chlor-9-H-purin-9-yl)-2-cyclopentene-1-methanol LONZA AG (CH) 2004-09-01 EP claimed
EP-1418170-A2 Process for the preparation of optically active amino alcohols by optical resolution Lonza AG (CH) 2004-05-12 EP claimed
US-6156893-A Process for the preparation of (1S,4R)- or (1R,4S)- 4-(2-amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1-methanol LONZA A.G. (CH) 2000-12-05 US claimed
EP-0926131-A2 Process for the preparation of aminoalcohol derivatives and their further transformation zu (1R,4S)-4-((2-amino-6-chlor-5-formamido-4-pyrimidinyl)-amino)-2-cyclopenten-1-methanol LONZA A.G. (CH) 1999-06-30 EP claimed
EP-0878548-A2 Multistep process for the preparation of (1S,4R)- and/or (1R,4S)-4-(2-Amino-6-Chlor-9-H-purin-9-yl)-2-cyclopentene-1-methanol LONZA AG (CH) 1998-11-18 EP claimed
JP-11228510-A None JP disclosed
EP-1982985-A2 Method for manufacturing a purine derivative Lonza AG (CH) 2008-10-22 EP disclosed
US-7358073-B2 Process for the preparation of aminoalcohol derivatives and their further conversion to (1R, 4S)-4(2-amino-6-chloro-5-formamido-4- pyrimidinyl)-amino-2-cyclopentenyl-1-methanol LONZA AG (CH) 2008-04-15 US disclosed
US-7338945-B2 Process for the preparation of aminoalcohol derivatives and their further conversion to (1R, 4S)-4(2-amino-6-chloro-5-formamido-4-pyrimidinyl)-amino-2-cyclopentenyl-1-methanol LONZA AG (CH) 2008-03-04 US disclosed
US-7338945-B2 Process for the preparation of aminoalcohol derivatives and their further conversion to (1R, 4S)-4(2-amino-6-chloro-5-formamido-4-pyrimidinyl)-amino-2-cyclopentenyl-1-methanol LONZA AG (CH) 2008-03-04 US disclosed
CN-1323057-C Process for the preparation of (1S,4R) or (1R,4S)-1-amino-4-(methylol)-2-cyclopentene and its derivatives or its salts LONZA AG (CH) 2007-06-27 CN disclosed
US-20070123545-A1 PROCESS FOR THE PREPARATION OF AMINOALCOHOL DERIVATIVES AND THEIR FURTHER CONVERSION TO (1R, 4S)-4(2-AMINO-6-CHLORO-5-FORMAMIDO-4- PYRIMIDINYL)-AMINO-2-CYCLOPENTENYL-1-METHANOL LONZA LTD. (CH) 2007-05-31 US disclosed
EP-0926131-A2 Process for the preparation of aminoalcohol derivatives and their further transformation zu (1R,4S)-4-((2-amino-6-chlor-5-formamido-4-pyrimidinyl)-amino)-2-cyclopenten-1-methanol LONZA A.G. (CH) 1999-06-30 EP disclosed
EP-0926131-A2 Process for the preparation of aminoalcohol derivatives and their further transformation zu (1R,4S)-4-((2-amino-6-chlor-5-formamido-4-pyrimidinyl)-amino)-2-cyclopenten-1-methanol LONZA A.G. (CH) 1999-06-30 EP disclosed
EP-0926131-A2 Process for the preparation of aminoalcohol derivatives and their further transformation zu (1R,4S)-4-((2-amino-6-chlor-5-formamido-4-pyrimidinyl)-amino)-2-cyclopenten-1-methanol LONZA A.G. (CH) 1999-06-30 EP disclosed
CN-1218795-A Process for the preparation of aminoalcohol derivatives and their further conversion to (1R,4S) -4- ((2-amino-6-chloro-5-formylamino-4-pyrimidinyl) amino) -2-cyclopentenyl-1-methanol LONZA AG (CH) 1999-06-09 CN disclosed
CN-1218795-A Process for the preparation of aminoalcohol derivatives and their further conversion to (1R,4S) -4- ((2-amino-6-chloro-5-formylamino-4-pyrimidinyl) amino) -2-cyclopentenyl-1-methanol LONZA AG (CH) 1999-06-09 CN disclosed
EP-0878548-A2 Multistep process for the preparation of (1S,4R)- and/or (1R,4S)-4-(2-Amino-6-Chlor-9-H-purin-9-yl)-2-cyclopentene-1-methanol LONZA AG (CH) 1998-11-18 EP disclosed
EP-0878548-A2 Multistep process for the preparation of (1S,4R)- and/or (1R,4S)-4-(2-Amino-6-Chlor-9-H-purin-9-yl)-2-cyclopentene-1-methanol LONZA AG (CH) 1998-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123545-A1 PROCESS FOR THE PREPARATION OF AMINOALCOHOL DERIVATIVES AND THEIR FURTHER CONVERSION TO (1R, 4S)-4(2-AMINO-6-CHLORO-5-FORMAMIDO-4- PYRIMIDINYL)-AMINO-2-CYCLOPENTENYL-1-METHANOL GART, AASDHPPT, TYMS NR1I2 1865/4885ALB 2272/4885PDE4D 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.